Vivos INC

Vivos Inc. announced the appointment of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, bolstering its leadership in targeted cancer therapies.

Vivos Inc. announced the appointment of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, strengthening its leadership in targeted cancer therapies.

Vivos Inc. announced the creation of Vivos Scientific India LLP, a wholly owned entity aimed at establishing manufacturing, expanding human therapies, and pursuing commercialization in India.

Vivos Inc. reports positive initial safety results and early signs of efficacy from its RadioGel Precision Radionuclide Therapy human clinical trials, leading to plans for trial expansion.

Vivos Inc. finalized the sale of 12,500,000 shares of common stock for $1.5 million and issued warrants to purchase 6,250,000 shares.

Vivos Inc. has submitted an application to the FDA for an Investigational Device Exemption to begin human clinical trials of its Radiogel Precision Radionuclide Therapy.

Vivos Inc. reports increased revenue and strategic advancements in its precision radionuclide therapy for both human and animal oncology, alongside ongoing financing efforts.

Vivos Inc. reported increased net losses and cash burn in Q3 2025, while advancing strategic initiatives in human and animal therapies and facing FDA regulatory hurdles.

Vivos Inc. reported a wider net loss in Q2 2025 due to increased operating expenses and R&D, despite a rise in revenue, as it continues to fund its Y-90 therapy development and global expansion.

Vivos Inc. reports increased revenue for Q1 2025, driven by IsoPet therapies and clinic certifications, but continues to face significant net losses and going concern uncertainties.

Vivos Inc. reported its financial results for the third quarter of 2024, highlighting ongoing efforts in the development of its RadioGel technology and its application in both animal and human therapies.

Vivos Inc. reports a net loss of $1.06 million for the six months ended June 30, 2024, while continuing to develop its RadioGel technology and seeking additional funding.

Vivos Inc.'s 2024 annual report details ongoing efforts in developing its RadioGel technology and expanding its IsoPet veterinary services, despite facing financial challenges and expressing doubt about its ability to continue as a going concern.

Vivos Inc.'s annual report details the company's focus on its RadioGel technology for cancer treatment, progress in the veterinary market with IsoPet, and ongoing efforts to secure FDA approval for human trials.

Brad Allan Weeks, President of Vivos Inc, purchased 92,000 shares of common stock on July 21, 2026 for $0.05 per share.

Brad Allan Weeks, President of Vivos Inc, purchased 60,000 shares of common stock on March 31, 2026 for $0.08 per share.

Michael K Korenko, CEO AND PRESIDENT and a Director of Vivos Inc, purchased 200,000 shares of common stock on July 15, 2026 for $0.06 per share.

Vivos Inc. President Brad Allan Weeks acquired 60,000 shares of common stock in two separate transactions.

Michael Korenko, CEO and President of VIVOS INC, acquired 150,000 shares of common stock at $0.0618 per share.

VIVOS Inc. CEO and President Michael K. Korenko is set to acquire 200,000 shares of common stock at $0.0646 per share in a pre-arranged transaction.